Literature DB >> 12527581

Guidelines on treatment of stage IIIB non-small cell lung cancer.

James R Jett1, Walter J Scott, M Patricia Rivera, William T Sause.   

Abstract

Stage IIIB includes patients with T4, any N, M0, and any T, N3, M0. Surgery may be indicated only for carefully selected T4N0M0 patients with or without neoadjuvant chemotherapy or chemoradiotherapy. Patients with N3 lymph node involvement are not considered as surgical candidates. For patients with unresectable disease, good performance score, and minimal weight loss, treatment with combined chemotherapy and radiotherapy has resulted in better survival than treatment with radiotherapy alone. Multiple daily fractions of radiotherapy have not resulted in improved survival compared with standard fractionation once daily. Concurrent chemoradiotherapy appears to be associated with improved survival compared with sequential chemotherapy and radiotherapy. Treatment of stage IIIB due to malignant pleural effusion is addressed in the section that deals with stage IV disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527581     DOI: 10.1378/chest.123.1_suppl.221s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Analogies between reading of medical and religious texts.

Authors:  Matthew Links
Journal:  BMJ       Date:  2006-11-18

2.  Atrial resection for lung cancer: morbidity, mortality, and long-term follow-up.

Authors:  Andreas Kuehnl; Michael Lindner; Hans-Martin Hornung; Hauke Winter; Karl-Walter Jauch; Rudolf A Hatz; Christian Graeb
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

3.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

4.  Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy.

Authors:  Tatsuro Okamoto; Takekazu Iwata; Teruaki Mizobuchi; Hidehisa Hoshino; Yasumitsu Moriya; Shigetoshi Yoshida; Ichiro Yoshino
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

Review 5.  The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis.

Authors:  Xinshuai Wang; Xuezhen Ding; Dejiu Kong; Li Zhang; Yibo Guo; Jing Ren; Xiaochen Hu; Junqiang Yang; Shegan Gao
Journal:  Int J Clin Oncol       Date:  2016-12-22       Impact factor: 3.402

6.  Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis.

Authors:  Yuyang Xu; Nan Chen; Zihuai Wang; Yingyi Zhang; Jiandong Mei; Chengwu Liu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

7.  The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study.

Authors:  Jie Yang; Yuan Zhang; Xiaoting Sun; Aaron M Gusdon; Nan Song; Linsong Chen; Gening Jiang; Yueye Huang
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-12       Impact factor: 4.553

8.  Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.

Authors:  Hao Jiang; Wei Zhao; Wei Shao
Journal:  Tumour Biol       Date:  2014-06-07

9.  Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination.

Authors:  Yi-Jiu Ren; Yun-Lang She; Chen-Yang Dai; Ge-Ning Jiang; Ke Fei; Chang Chen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-12-24

10.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.